What is Global PD-L1 Biomarker Testing Market?
The Global PD-L1 Biomarker Testing Market is a rapidly evolving sector that focuses on the detection and analysis of the PD-L1 biomarker, a protein that plays a crucial role in cancer immunotherapy. This market is driven by the increasing prevalence of cancer worldwide and the growing need for personalized treatment strategies. The PD-L1 biomarker testing allows healthcare professionals to identify patients who are most likely to benefit from PD-1/PD-L1 inhibitors, a class of drugs that has shown significant promise in the treatment of various types of cancer. The global market for PD-L1 biomarker testing is characterized by the presence of several key players who offer a range of testing solutions, including assays and kits, to cater to the diverse needs of the healthcare sector.
PD-L1 (22C3), PD-L1(28-8), PD-L1 (SP142), PD-L1 (SP263), Other in the Global PD-L1 Biomarker Testing Market:
The Global PD-L1 Biomarker Testing Market is segmented based on the type of PD-L1 clone used in the test. These include PD-L1 (22C3), PD-L1(28-8), PD-L1 (SP142), PD-L1 (SP263), and others. Each of these clones has its unique characteristics and is used in different testing scenarios. For instance, PD-L1 (22C3) is widely used in testing for non-small cell lung cancer (NSCLC), while PD-L1 (SP142) is often used in testing for triple-negative breast cancer (TNBC). The choice of clone depends on various factors, including the type of cancer, the patient's medical history, and the specific requirements of the treatment plan.
Hospital, Diagnostic Center, Others in the Global PD-L1 Biomarker Testing Market:
The Global PD-L1 Biomarker Testing Market finds its applications in various settings, including hospitals, diagnostic centers, and others. In hospitals, PD-L1 biomarker testing is used to guide the treatment of patients with cancer, helping doctors to determine the most effective course of action. In diagnostic centers, these tests are used to provide accurate and timely diagnoses, enabling early intervention and improving patient outcomes. Other applications of PD-L1 biomarker testing include research institutions, where these tests are used in the development of new drugs and treatment strategies.
Global PD-L1 Biomarker Testing Market Outlook:
In 2023, the Global PD-L1 Biomarker Testing Market was valued at US$ 1470.5 million. It is projected to reach a staggering US$ 14870 million by 2030, growing at a compound annual growth rate (CAGR) of 38.7% during the forecast period from 2024 to 2030. Hospitals account for the largest share of the PD-L1 Biomarker Testing market, with a proportion of about 52.7% in 2019. Geographically, North America holds the largest market share, accounting for nearly 55.63% of the global consumption in 2019.
| Report Metric | Details |
| Report Name | PD-L1 Biomarker Testing Market |
| Accounted market size in 2023 | US$ 1470.5 million |
| Forecasted market size in 2030 | US$ 14870 million |
| CAGR | 38.7% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
